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but these laws are neither universal nor consistent. This study estimates the hospital-
wide prevalence, cost, and mortality of CLABSI-associated discharges for all US 
community hospitals. Hypotheses are that CLABSI prevalence and mortality are 
increasing and cost is unchanged. METHODS: Data for the study was extracted from 
the AHRQ HCUP National Inpatient Sample (NIS) database for 2002 and 2006. 
CLABSI was deﬁned as a discharge with an ICD9-CM procedure code for a central 
line procedure (38.92, 38.93, and 38.95) and an ICD9-CM diagnosis code for a 
BSI (24 codes). SAS Proc Surveyreg was used to estimate (log of) cost, and Surveylo-
gistic was used to estimate mortality and CLABSI prevalence. NIS weights were used 
to make national estimates, charges were adjusted using cost-to-charge ratios, and 
costs were adjusted to 2006 US dollars using the hospital service CPI. RESULTS: 
Average cost of a CLABSI-related hospitalization was $31,879 in 2006 dollars. Pres-
ence of CLABSI had a positive signiﬁcant effect on cost (0.128, p  0.001), as did the 
number of procedures (0.125, p  0.001) and LOS (0.034, p  0.001) while being 
female had a signiﬁcant negative effect (0.027, p  0.001). The time variable was not 
signiﬁcant (0.056, p  0.052). OR for CLABSI increased over time (1.196, p  0.001) 
when controlling for gender, LOS, number of procedures, liver disease, and renal 
failure. For mortality signiﬁcant ORs (p  0.001) were time (0.761), female (0.875), 
LOS (0.982), age (1.026), number of procedures (1.204), liver disease (1.814), 
and CLABSI (2.348). CONCLUSIONS: CLABSI-related hospital mortality in the 
US is decreasing as is the cost of treatment. However, the prevalence of CLABSI is 
increasing.
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THOUGHTS ON THE LABORATORY CULTURES REIMBURSED BY  
THE SOCIAL SECURITY IN AUSTRIA (OUTPATIENT SECTOR IN 
PHYSICIANS’ CARE AND INSTITUTES, BUT NOT HOSPITAL 
OUTPATIENT CARE)
Wilbacher I, Endel G
Main Association of Austrian Social Security Institutions, Vienna, Vienna, Austria
OBJECTIVES: If a patient shows an infection, the physician has to decide which kind 
of anti-infective substance has to be prescribed. One method to ﬁgure this out is to 
order laboratory cultures. We want to ﬁnd out whether there is a correlation between 
the frequencies of cultures reimbursed and the number of prescriptions of anti-infective 
agents. METHODS: Claims data (2006) from physicians in free practice and institutes 
for laboratory medicine data for laboratory cultures were conducted out of different 
reimbursement catalogs in Austria. RESULTS: The rate of reimbursed cultures per 
prescription was 11% (for bacterial cultures and antibacterial medication J01, J04), 
63% (for mycotic cultures and antimycotic medication J02), 24% for viral cultures 
and antiviral medication J05) and 25% (for parasitic cultures and antiparasitical 
medication P01,02,03). If just those infections veriﬁed by cultures had caused a pre-
scription, the costs for anti-infective agents would have been 17% of the current 
number. If all prescriptions for anti-infective agents had been based on a culture, the 
prescription costs would have been 7,5 times higher. There are price differences for 
cultures due to various contract partners. If the lowest fee had been paid for each test 
we would have saved 33% of the current turnover for bacterial, 37% for mycotic, 
38% for viral, and 6% for parasitic infections. If the highest price had been paid we 
would have paid 75% (bacterial), 46% (mycotic), 164% (viral) and 33% (parasitic) 
more than the current turnover. CONCLUSIONS: Our further research will focus on 
the different categories of prescription for anti-infective agents, testing and also the 
guideline conformity of its use.
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DIRECT MONTHLY HAART SUPPLY AT THE AIDS CENTER— 
A COST-EFFECTIVE MODE TO INCREASE ADHERENCE AND OUTCOME
Elbirt D1, Asher I1, Cohen Y1, Gradstein S1, Werner B1, Burke M1, Hammerman A2,  
Klang SH2, Sthoeger Z1
1Kaplan Medical Center, Rehovot, Israel, 2Clalit Health Services, Tel-Aviv, Israel
OBJECTIVES: To determine the cost effectiveness of direct monthly supply of 
HAART (Highly active anti retroviral therapy) medications at the AIDS center. 
METHODS: We analyzed 385 HIV patients, mostly (90%) immigrants from Africa 
(HIV subtype C) that were treated with HAART for more than one year prior to the 
initiation of the study. During the ﬁrst two years of the study, all patients received 
HAART prescriptions and the medications were supplied by local pharmacies. There-
after (next 2 years) all patients received their medications, monthly, by a nurse (on a 
part-time job basis) at our AIDS center. Compliance, immunological (CD4) and viro-
logical (VL) outcome between the two study periods (modes) were compared. 
RESULTS: The mean age of our patients, 48% males, at time of study initiation was 
35 o 13 (mean o SD) years. The mean time from HIV diagnosis was 7.3 o 4.1 years. 
Following the ﬁrst 2 years, 75% of the patients attended more then 90% of scheduled 
visits with 57% treatment adherence (90% of prescriptions). The mean CD4 count 
at the end of this period was 324.8 o 220.9 cell/mcl (66.7%  200 cells/mcl). Virologi-
cal failure (VL  40 copies/ml) was observed in 53% (mean VL 182,918 o 834,916 
copies/ml) of the treated patients. As a result of our intervention (two years of direct 
HAART supply), visits and treatment compliance increased, signiﬁcantly (p  0.001), 
to 90% and 84%, respectively. Concomitantly the CD4 cell counts increased to 470 
o 266 cell/mcl (p  0.24 compared to the ﬁrst study period) with 83.6% CD4 counts 
200 cells/mcl (p  0.001). A low rate of virological failures (28%; p  0.001; mean 
VL 15,068 o 73,382 copies/ml; p  0.001) was observed. CONCLUSIONS: Direct 
monthly supply of HAART medications at the HIV center is a very low cost mode 
which signiﬁcantly improves patient’s adherence as well as immunological and viro-
logical outcome.
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SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB 
IN HIGH-RISK PATIENTS
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OBJECTIVES: Palivizumab has been shown to reduce the number of respiratory syn-
cytial virus (VSR) related hospitalizations in preterm infants and patients with bron-
chopulmonary dysplasia or congestive heart disease. It is widely used but its high price 
raises concerns about its cost-effectiveness. The aim of this study was to systematically 
review economic evaluations (EE) of palivizumab in high-risk patients. METHODS: 
A comprehensive search for literature on the cost-effectiveness of palivizumab versus 
no prophylaxis was conducted. Bibliographic databases were searched from September 
2001 to February 2008. Additional relevant studies were identiﬁed from manual 
searches. Only studies published in English and Spanish were included. Quality was 
assessed using the Drummond criteria for EE. Two independent reviewers scrutinized 
retrieved references and assessed the quality of the studies. RESULTS: Twenty refer-
ences were included, representing a total of 32 EE: 20 cost-effectiveness analyses 
(CEA), 10 cost-utility analyses (CUA) and 2 cost-beneﬁt analyses (CBA). Quality was 
variable. Populations varied widely with some studies including all high-risk patients 
and others focusing on speciﬁc subgroups. Results were reported as incremental cost-
effectiveness ratios in terms of cost per hospitalization prevented, life-year gained or 
quality-adjusted life-year in all CEA and ACU and as cost-beneﬁt ratios in CBA. Esti-
mates of incremental ratios ranged from cost savings to incremental costs of a high 
order of magnitude. Assumptions on hospitalization rates in intensive care units, 
mortality and long-term consequences due to RSV infections, as well as acquisition 
cost of palivizumab seem to be related with more favourable ratios. A tendency for 
better results was also observed in studies receiving ﬁnancial support from the manu-
facturer. CONCLUSIONS: A true determination of cost-effectiveness of palivizumab 
is difﬁcult. However, costs of palivizumab seem to exceed potential cost-saving from 
reduced admission rates and might only prove to be cost-effective in a small subset of 
very high risk patients.
PIN80
THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH 
TECHNOLOGY ASSESSMENT (HTA) OF VACCINES—LESSONS 
LEARNED FROM FINLAND
Laine J1, Soini EJ2, Martikainen JA3
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OBJECTIVES: The aim of economic evaluation (EE) is to provide information to help            
decision makers maximize health beneﬁts with given resources or advise how to attain 
given health targets efﬁciently in society. We examined the role and weight of EE in 
the HTA of vaccines in Finland and explored how EEs have and should have been 
conducted. METHODS: The methods and perspective of national EEs related to         
rotavirus and pneumococcal conjugate vaccination programs were evaluated. An 
ofﬁcial call for a rotavirus vaccination tender, competitive bidding process and tender 
decision-making criteria were explored. RESULTS: EE can have a crucial role when       
a new vaccine is considered for inclusion in a national vaccination program, which is 
necessary before a tender call for bids can be given. However, for tenders the pre-
dominant decision-making criterion seemed to be cost per vaccine. EE seemed to be 
conducted using a pair-wise comparison instead of multiple comparisons (i.e. different 
vaccines for a certain disease are compared only to no vaccination strategy). Advanced 
methods to characterize uncertainty, such as cost-effectiveness acceptability frontiers 
and value-of-information analyses, have not been applied. Also, no speciﬁc cost-effec-
tiveness threshold for new vaccines has been set in Finland although international 
references and Finnish home dialysis and bypass surgery thresholds have been cited 
in the evaluation reports. However, the literature revealed that setting a threshold may 
be impossible. Thus, we present an ideal EE process that enables value-based threshold 
pricing for manufacturers and decisions that can lead to efﬁciency. CONCLUSIONS: 
There is a discrepancy between the scientiﬁc principles and objectives of EE and real 
life in terms of national EEs of vaccines and tender calls in Finland. The current 
practice does not necessarily lead to optimal decisions based on cost-effectiveness. 
Particularly, multiple comparisons with valid prices should be encouraged.
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MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF 
PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING 
CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS
Endel G1, Schiller—Frühwirth I1, Urach C2, Popper N2, Zauner G2
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OBJECTIVES: The aim of the current work is to implement a Markovian-model and 
a Differential Equation Model for simulating the pneumococcal illnesses and estimate 
the possibility of preventing the disease by vaccination of infants with the 7-valent 
serum. Implementing the two models opens the possibility of comparison of both and 
offers better insights on the inﬂuence of non linear effects like herd immunity and 
serotype replacement. METHODS: To assess the epidemiological inﬂuence of pneu-
mococcal infant vaccination using PCV7 in Austria a static Markovian-model and 
ordinary differential equation (ODE) modeling and simulation techniques are used. 
The Markovian model approach was classiﬁed as state of the art using a systematic 
literature review. (334 abstracts, 45 papers in detail) Implementing a model for serious 
diseases (meningitis, septicaemia and bacteraemic pneumonia) based on an infection 
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with penumococci, several boundaries and weaknesses in modeling occur: only steady 
state analysis possible; no dynamic implementation of herd immunity and replacement 
effects; and no inﬂuence of changing demographic structure over time Therefore a 
comparable ODE system was implemented and extended by population dynamics and 
splitting the pneumococcal serotypes in groups depending on their behavior depending 
on immunization. RESULTS: For standard immunization program implementation as 
advocated by EPAR/EMEA it was possible to reproduce the behaviour of the Markov-
ian-Model with the ODE approach resulting in equivalent outcomes for validation.
Using ODE approach extensions the inﬂuence of population dynamic effects with and 
without immunization is compared in detail. Using the mathematical theory for ODEs 
stability and uniqueness of the implemented approach was shown. CONCLUSIONS: 
The Markovian model can accurately describe the infection with pneumococcal bac-
teria if proper data exists and if there is no need to use dynamic effects or feedback-
loops. The ODE model offers possibilities to implement additional dynamic methods, 
which is essential to gather the real world dynamics.
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PROTEIN D CONJUGATE VACCINE IN ITALY
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OBJECTIVES: The aim of this project is to generate an assessment for the new pneu-             
mococcal non-typeable Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-
CV) in Italy. Currently, pneumococcal vaccination is not recommended nationally,          
but many regions adopted 7-valent pneumococcal (PCV-7) vaccination.    METHODS: 
The project was performed using the Health Technology Assessment (HTA) methodol-
ogy with a large input of multidisciplinary panel of experts with different backgrounds 
such as clinicians, epidemiologists and health economists. RESULTS: Literature and  
national database review revealed at least 300 pneumococcal meningitis and 4.000 
pneumococcal bacteremia cases per year in Italy. The additional pneumococcal sero-
types (ST) included in PHiD-CV (ST1, 5 and 7F) account for at least 10% of all 
Invasive Pneumococcal Disease (IPD) cases. The amount of pneumococcal and NTHi 
pneumonia cases was estimated at around 70.000 cases per year. More than one 
million infant episodes of otitis media (OM) are reported annually. Around 50% of 
these cases are caused by two bacteria, Streptococcus pneumonia and NTHi. The total 
annual direct medical cost related to pneumococcal and NTHi disease could exceed 
110 million Euros in Italy. Modelling the impact of PHiD-CV vaccine with a cohort 
model populated with Italian data shows a huge health gain in IPD, pneumonia and 
OM. The new vaccine demonstrates superior clinical results and important cost-offsets 
compared with no vaccination. It dominates as well the current vaccination option of 
PCV-7, leading to signiﬁcant cost savings. CONCLUSIONS: Pneumococcal vaccina-
tion emerges as an important public health improvement in Italy; at the same price, 
PHiD-CV appears the preferable choice for routine child immunization programs.
MUSCULAR-SKELETAL DISORDERS – Clinical Outcomes Studies
PMS1
RISK ASSESSMENT OF CARDIOVASCULAR THROMBOTIC EVENTS, 
OTHER CARDIAC EVENTS, AND MORTALITY AMONG VETERANS 
AFFAIRS PATIENTS WITH DIFFICULT TO MANAGE GOUT
Raisch DW1, Rice J2, Campbell HM2
1University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 2Department of 
Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA
OBJECTIVES: Gout patients in the Department of Veterans Affairs (VA) are often 
difﬁcult to manage (DTM) with multiple co-morbidities (diabetes, hypertension, renal 
disease) that are associated with cardiovascular thrombotic events (CVTE) and other 
cardiac events (OCE). Our objectives were to describe rates of CVTE and OCE among 
patients with gout and to determine if increased CVTE or OCE occurred in patients 
with DTM gout. METHODS: We used VA national databases to select all patients 
with gout diagnoses (ICD-9  274.xx) in an index year of 2004 with follow-up 
through 2006. We identiﬁed patients with ICD-9 codes for OCEs and CVTE diagno-
ses, based upon deﬁnitions from the Antiplatelet Trialists’ Collaboration. ICD-9 codes 
for gout nephropathy or tophi were used to identify DTM patients. We calculated 
odds ratios with 95% conﬁdence intervals (OR, CI) to compare risk of CVTE, OCE, 
and mortality among DTM versus other gout patients. RESULTS: Of 156,809 VA 
gout patients, 2534 (1.6%) had CVTE and 9759 (6.2%) had OCE in 2004. Rates 
were similar for 2005 and 2006: 1.6% and 1.3% for CVTE, 6.2% and 5.7% for 
OCE. DTM patients, deﬁned as having diagnostic codes of gout nephropathy (ICD-9 
of 274.1x, n  1667) and/or tophi (ICD-9 of 274.8x, n  1780), had similar rates of 
CVTE as other gout patients in 2004 (1.9% vs. 1.6%, OR  1.16, CI  0.90–1.50), 
but increased risk in 2005 (2.2% vs. 1.5%, OR  1.41, CI  1.13–1.77) and 2006 
(2.0% vs. 1.3%, OR  1.54, CI  1.23–1.93). OCEs were signiﬁcantly greater each 
year in DTM gout patients; 2004: 9.9% vs. 7.6%, OR  1.33, CI  1.19–1.50; 2005: 
11.1% vs. 7.4%, OR  1.57, CI  1.41–1.74; 2006: 11.3% vs. 6.8%, OR  1.75, CI 
 1.58–1.94. Mortality was signiﬁcantly greater in DTM gout patients; 2004: 3.3% 
vs. 4.0%, OR  1.21, CI  1.01–1.44; 2005: 3.3% vs. 4.8%, OR  1.49, CI  1.28–
1.73; 2006: 3.2% vs. 4.6%, OR  1.49, CI  1.27–1.73. CONCLUSIONS: Patients 
with DTM gout have greater risks for CVTEs, OCEs, and mortality.
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SAFETY OF LEFLUNOMIDE, METHOTREXATE AND SULFASALAZINE: 
ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL 
DRUG MONITORING
Golicki D1, Lis J2, Niewada M1
1Medical University of Warsaw, Warsaw, Poland, 2Sanoﬁ-Aventis, Warsaw, Poland
OBJECTIVES: Comparison of leﬂunomide, methotrexate and sulfasalazine safety 
based on data from WHO Programme for International Drug Monitoring. METHODS: 
The data from countries participating in the World Health Organization Programme 
for International Drug Monitoring are collected and maintained, on behalf of the 
WHO, by the Uppsala Monitoring Centre, in the Vigibase. An analysis of data on 
adverse events (AE) of leﬂunomide, methotrexate and sulfasalazine reported to Vigi-
base since 2000 up to 16th March 2009 (ref: ER18-2009), was performed. RESULTS: 
The total number of 16,311 individual case reports of leﬂunomide adverse events were 
registered in the Vigibase, compared to 32,945 and 5,011 for methotrexate and sul-
fasalazine, respectively. There were 108 death cases registered for leﬂunomide, 236 
for methotrexate and 18 for sulfasalazine. Most frequent system-organ classes reported 
were: gastro-intestinal system disorders (13.2%) and skin and appendages disorders 
(9,8%) for leﬂunomide, respiratory system disorders (11.6%) and general disorders 
(10.8%) for methotrexate and skin and appendages disorders (17.7%) and general 
disorders (14.6%) for sulfasalazine. Most frequent AE reports for leﬂunomide were: 
diarrhoea (588 cases versus 303 and 58 for methotrexate and sulfasalazine, respec-
tively), dyspnoea (310 vs. 563 vs. 53), hepatic function abnormal (304 vs. 262 vs. 78), 
nausea (272 vs. 401 vs. 90), rash (270 vs. 181 vs. 209), hypertension (265 vs. 138 vs. 
6) and anaemia (242 vs. 383 vs. 55). Congenital abnormalities were reported in 26 
leﬂunomide, 204 methotrexate and 15 sulfasalazine patients. CONCLUSIONS: WHO 
data indicates that leﬂunomide is at least as safe as methotrexate. All three disease 
modifying drugs have different spectrum of adverse events.
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PROPORTION OF PATIENTS WITH OSTEOPOROSIS IN 
POSTMENOPAUSAL WOMEN PERFORMING A BONE MINERAL DENSITY 
DIAGNOSIS MEASUREMENT: THE PRESAGE STUDY
Guggenbuhl P1, Dufour R2, Liu-Leage S3, Tcherny S3, Sapin H3, Cortet B4
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OBJECTIVES: The primary objective was to estimate the proportion of patients suf-
fering from osteoporosis among postmenopausal women who could beneﬁt from 
therapeutic recommendations according to the French guidelines after performing a 
BMD diagnosis measurement. METHODS: Cross sectional observational study was 
performed of postmenopausal women, not treated for osteoporosis for at least one 
year and who could beneﬁt from therapeutic recommendations according to the 
French guidelines after performing a BMD. RESULTS: A total of 647 postmenopausal 
women were enrolled (646 analyzed) by 78 rheumatologists performing BMD mea-
surement between May 2007 and January 2008. The BMD measurement were pre-
scribed by rheumatologists (42.6%), GPs (34.1%), Ob/Gynecologist (18.1%) or other 
physicians (5.1%). The mean age was 66 o 9 years. According to the WHO deﬁnition, 
densitometry osteoporosis diagnosis was made in 57.6% patients (IC95% 53.7; 61.4), 
osteopenia diagnosis in 38.7% patients (IC95% 34.9; 42.6); and a normal BMD was 
established in 3.7% patients. A total of 39.7% of patients had at least a prevalent 
fracture and a treatment other than calcium and vitamin D supplementation was rec-
ommended in 93.0% cases of osteoporosis, in 44.8% in case of osteopenia and 8.3% 
in case of normal BMD. In a logistic regression model, the factors inﬂuencing thera-
peutic decision making in this population were the osteoporosis diagnosis versus 
osteopenia diagnosis OR  21.0 (IC95% 12.5; 35.3), past or current glucocorticoids 
use OR  2.7 (IC95% 1.3; 5.7). The fracture type was also important in decision making; 
existing vertebral fracture versus none OR  17.2 (IC95% 5.8; 51.4), existing non ver-
tebral fracture versus none OR  4.7 (IC95% 2.7; 8.4). CONCLUSIONS: In a real 
setting, osteoporosis was diagnosed in approximately 60% of the women who under-
went a BMD diagnosis and who complied with the French therapeutic guidelines. 
Therapeutic recommendations decision making was inﬂuenced mainly by BMD 
results, followed by prevalent fracture and fracture types and glucocorticoids use.
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EUROQOL-5 DIMENSION HEALTH STATUS QUESTIONNAIRE RESULTS 
FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-
CONTROLLED PHASE 3 STUDY OF TAPENTADOL EXTENDED RELEASE 
(ER) FOR THE MANAGEMENT OF CHRONIC OSTEOARTHRITIS KNEE 
PAIN
Kavanagh S1, Ashworth J2, Lange B2, Etropolski MS3, Van Hove I4, Rauschkolb C3
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OBJECTIVES: To evaluate the efﬁcacy and safety of the centrally acting analgesic, 
tapentadol ER, for the management of moderate to severe osteoarthritis knee pain; 
health status was evaluated using the EuroQol-5 Dimension (EQ-5D) questionnaire. 
